Digitisation | November 11, 2025
Nitinotes secures CE mark for automated suturing platform ‘EndoZip’
Enabling a new era in minimally invasive obesity treatment across Europe
Enabling a new era in minimally invasive obesity treatment across Europe
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Subscribe To Our Newsletter & Stay Updated
